Pharmaceutical companies

"The Pharmaceutical Industry Has a Large Amount of Control Over the Field of Oncology"

In the second part of our two-part interview with Daniel Goldstein, MD, an oncologist who studies the influence of business interests on healthcare, we talk...

When Medical Experiments Serve the Business Needs of Pharmaceutical Firms Instead of Science

The first part of a two-part interview with Daniel Goldstein, MD, an oncologist who also studies the influence of business interests on healthcare—from treating patients...

Are “Pay for Delay” Settlements in Patent Litigation Collusive?

A new study suggests that “pay for delay” settlements–in which generic drug manufacturers that challenge the patents of branded drug firms agree to drop...

LATEST NEWS

Tech Platforms and the Antitrust Duty to Deal

Why is there a widespread view that existing American antitrust law is ill-equipped to address dominant platforms that exclude or discriminate against...

Study: the Covid-19 Eviction Moratoriums Helped Reduce Food Insecurity and Mental Stress

A new study investigates the impact of 2020 Covid-19 rental eviction moratoria on the wellbeing of US households, finding that eviction moratoria...

Cogs and Monsters: Is Economics Destined to Remain a Dismal Science?

In her bold new book Cogs and Monsters: What Economics Is, and What It Should Be, Cambridge professor Diane Coyle offers a...

Is there a “California Effect” in Data Privacy Law? Why the EU is Not the World’s Privacy Cop

It is common lore in data privacy law and other fields that stringent regulatory standards (such as the ones introduced in the...

Governments Were Forced to Restrict Civil Liberties to Deal With Covid-19. More Flexible Constitutions Could Prevent That From Becoming the New Normal

A new paper argues that exploitation of gaps within democratic constitutions during emergencies, such as the Covid-19 pandemic, has the potential to...